MGRS — Monoclonal Gammopathy of Renal Significance
A small clone, a nephrotoxic antibody, a kidney in the crossfire.
MGRS is a clonal plasma-cell or B-cell disorder that secretes a nephrotoxic monoclonal immunoglobulin yet does not meet the tumour-burden criteria to treat an overt haematologic malignancy. The term was coined precisely so these patients are no longer dismissed as having a gammopathy of undetermined significance — once a monoclonal protein is shown to be injuring the kidney, the “significance” is anything but undetermined, and the patient can be offered clone-directed therapy.
of monoclonal-gammopathy + CKD patients have MGRS on biopsy
Klomjit & Zand, Kidney Int 2025 · PMID 40403931
MGUS prevalence at age ≥50 — the pool MGRS hides within
Kyle et al., NEJM 2006 · PMID 16571879
of MGRS biopsies are AL amyloidosis — the commonest lesion
Klomjit & Zand, Kidney Int 2025 · PMID 40403931
of PGNMID cases have a detectable serum or marrow clone
Bridoux et al., NDT 2021 · PMID 33494099
The lesions of MGRS
The monoclonal immunoglobulin injures the kidney through a handful of recurring patterns, grouped by how the protein deposits — as organized fibrils and microtubules, as non-organized granular deposits or complement dysregulation, or by directly poisoning the proximal tubule.
Organized deposits
Immunoglobulin self-assembles into fibrils or microtubules with a recognizable ultrastructure.
AL / AH / AHL Amyloidosis
AmyloidMisfolded monoclonal light chains (AL, most common), heavy chains (AH) or both aggregate into β-pleated-sheet fibrils that deposit in glomeruli, vessels and interstitium. Often systemic — heart, liver, nerve.
- Deposit
- Monoclonal light chain (λ > κ in AL), heavy chain, or both
- Pattern
- Nephrotic-range proteinuria; Congo-red positive with apple-green birefringence
- Ultrastructure
- Randomly arranged fibrils ~8–12 nm; typed best by laser microdissection + mass spectrometry
Cryoglobulinemic GN (Type I / II)
Cryo-GNCold-precipitating immunoglobulins deposit in glomerular capillaries. Type I is a single monoclonal Ig (the MGRS-relevant form); Type II is monoclonal IgM with rheumatoid-factor activity plus polyclonal IgG.
- Deposit
- Monoclonal IgM/IgG (Type I); monoclonal IgM + polyclonal IgG (Type II)
- Pattern
- Membranoproliferative morphology with intraluminal pseudothrombi
- Ultrastructure
- Subendothelial deposits with microtubular / 'fingerprint' substructure
Immunotactoid Glomerulopathy
ITGRare glomerular disease with proteinuria, hematuria and kidney dysfunction. Monoclonal ITG has an underlying hematologic disorder in ~two-thirds of cases; renal response tracks the hematologic response.
- Deposit
- Monoclonal Ig (usually IgG) with light-chain restriction
- Pattern
- Proliferative GN; frequent recurrence after transplant
- Ultrastructure
- Hollow-cored microtubules, typically >30 nm, in parallel arrays
Fibrillary GN
FGNGlomerular deposition of randomly arranged fibrils (12–24 nm, Congo-red negative).
- Deposit
- Usually polyclonal IgG (NOT MGRS); rare monoclonal light-chain-restricted variant
- Pattern
- Mesangial/MPGN; usually no detectable serum monoclonal protein
- Ultrastructure
- Randomly arranged fibrils ~12–24 nm; DNAJB9-positive by IHC/mass spec
The DNAJB9 discovery reclassified this entity: the vast majority of fibrillary GN is DNAJB9-positive and polyclonal — and is NOT MGRS. Only the rare monoclonal subset qualifies.
Non-organized deposits
Granular or amorphous deposition along basement membranes, or complement-driven injury.
Monoclonal Ig Deposition Disease
MIDDNon-amyloid, Congo-red-negative granular deposition of monoclonal light chains (LCDD), heavy chains (HCDD) or both (LHCDD) along basement membranes, causing Randall-type nodular glomerulosclerosis.
- Deposit
- Monoclonal κ light chain (LCDD); truncated heavy chain (HCDD); both (LHCDD)
- Pattern
- Nodular mesangial sclerosis with nephrotic proteinuria; often systemic
- Ultrastructure
- Granular, powdery electron-dense deposits along tubular & glomerular basement membranes (linear on IF)
Proliferative GN with Monoclonal Ig Deposits
PGNMIDGranular glomerular deposits of monotypic IgG (most often IgG3 κ), a single heavy-chain subclass and light chain, plus complement. A detectable serum/marrow clone is found in only ~30%.
- Deposit
- Monotypic IgG (predominantly IgG3, κ-restricted); rarer light-chain-only / IgA / IgM
- Pattern
- Membranoproliferative or endocapillary proliferative, glomerular-limited
- Ultrastructure
- Granular amorphous deposits, predominantly subendothelial / mesangial
2025 nuance: immunoglobulin-repertoire sequencing showed PGNMID-IgG3 is most often oligo/polyclonal — not from a clonal disorder — so these cases arguably should no longer be classified as MGRS. PGNMID is now understood as heterogeneous.
C3 Glomerulopathy with Monoclonal Gammopathy
C3G-MGThe monoclonal Ig acts not as a structural deposit but by dysregulating the alternative complement pathway — as an autoantibody to complement regulators or a C3-nephritic-factor-like driver — producing immunoglobulin-poor, C3-dominant injury.
- Deposit
- C3-dominant glomerular deposits; the pathogenic monoclonal Ig is in serum
- Pattern
- Membranoproliferative; dense-deposit disease or C3GN subtypes
- Ultrastructure
- C3-dominant staining with scant/absent immunoglobulin
Tubular / crystalline
Light chains injure the proximal tubule directly — as crystals in tubular cells or histiocytes.
Light Chain Proximal Tubulopathy / Fanconi
LCPTFiltered monoclonal light chains (usually κ) are endocytosed by proximal tubular cells and either crystallize or accumulate, impairing reabsorption and producing acquired Fanconi syndrome with slowly progressive CKD. Usually low tumor-burden clones.
- Deposit
- Monoclonal light chain (predominantly κ) within proximal tubular cytoplasm
- Pattern
- Fanconi syndrome — glycosuria, phosphaturia, aminoaciduria, proximal RTA
- Ultrastructure
- Intracytoplasmic crystalline (rhomboid/needle) inclusions, or amorphous lysosomal accumulation
Crystal-Storing Histiocytosis
CSHMonoclonal light chains crystallize within histiocytes/macrophages (rather than tubular cells), which accumulate in the renal interstitium and extrarenal sites. Associated with low-grade lymphoplasmacytic disorders.
- Deposit
- Monoclonal light chain (usually κ) within histiocyte cytoplasm
- Pattern
- Tubulointerstitial sheets of crystal-laden histiocytes
- Ultrastructure
- Intracytoplasmic crystalline inclusions within histiocytes
How a paraprotein injures the kidney
A single clone, secreting a single abnormal antibody, finds several distinct ways to break a nephron.
The whole intact immunoglobulin or its free light chains precipitate along basement membranes and in the mesangium — granular in MIDD and PGNMID, expansile and nodular in Randall-type sclerosis — physically distorting filtration.
Misfolded light chains self-assemble into ordered ultrastructures: β-pleated-sheet amyloid fibrils, the hollow microtubules of immunotactoid GN, or the substructured deposits of cryoglobulinaemia — congophilic or not, but unmistakable on EM.
In C3 glomerulopathy the antibody never deposits as a structure at all. It acts catalytically — as an autoantibody to a complement regulator or a C3-nephritic-factor-like driver — unleashing the alternative pathway for immunoglobulin-poor, C3-dominant injury.
Filtered light chains are endocytosed by proximal tubular cells, where they crystallize or overwhelm lysosomes — driving acquired Fanconi syndrome — or precipitate inside histiocytes as crystal-storing histiocytosis.
The MGRS workup
MGRS lives at the seam between haematology and nephrology — confirming it requires interrogating both the clone and the kidney. The sequence runs from serum and urine screening to the indispensable biopsy.
- 1
Serum & urine electrophoresis + immunofixation
Detect and characterize the monoclonal protein (SPEP/UPEP/IFE).
- 2
Serum free light chains + involved/uninvolved ratio
More sensitive for light-chain-only clones; an abnormal ratio is a key MGRS predictor.
- 3
Bone marrow biopsy + flow / FISH
Identify and size the clone — plasma-cell vs B-cell — to direct therapy.
- 4
Kidney biopsy with IF + EM
Indispensable: light microscopy, immunofluorescence (isotype + light/heavy chain) and electron microscopy define the lesion.
- 5
Ancillary techniques
Pronase-digested IF, IgG-subclass staining, DNAJB9 IHC, and laser microdissection + mass spectrometry for definitive typing.
- 6
Mayo MGRS Prediction Tool (2025)
Estimates the probability of an MGRS lesion on biopsy from 8 predictors (AUC 0.896); helps decide whom to biopsy.
Treatment: treat the clone
Treat the clone, not just the inflammation. Therapy is clone-directed — target the specific plasma-cell or B-cell clone producing the nephrotoxic immunoglobulin. The depth of hematologic response strongly predicts renal recovery.
For AL amyloidosis the standard of care is now daratumumab + CyBorD (Dara-VCd), established by the ANDROMEDA trial. Autologous stem-cell transplant is an option in eligible patients.
Targets the CD20+ clone driving lesions such as cryoglobulinemic GN and many cases of monoclonal immunotactoid glomerulopathy.
The central unsolved challenge — when no clone is detectable (e.g. some PGNMID/ITG), empiric therapy is often used while the field searches for the driver.
Kidney transplantation is potentially transformative but the untreated clone causes high allograft recurrence; achieving a deep hematologic response before transplant reduces recurrence and improves outcomes.
Evidence (2025–2026)
Every claim above traces to a verified PubMed citation. The field is moving fast — the most recent consensus and reclassification papers are highlighted first.
Educational synthesis grounded in PubMed and the 2025 RPS/IKMG terminology consensus. Not medical advice.